Peter Black, MD
Affiliations: | 1987-2006 | Neurosurgery | Brigham and Women's Hospital, Boston |
Google:
"Peter Black"Children
Sign in to add trainee| Richard Ellenbogen | division chief | Brigham and Women's Hospital, Boston |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mostafid H, Babjuk M, Bochner B, et al. (2020) Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology |
| Au S, Keyes M, Black P, et al. (2020) Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. Pathology, Research and Practice. 152822 |
| Necchi* A, Raggi D, Briganti A, et al. (2020) MP55-09 ASSOCIATION OF AN IMMUNE-GENE SIGNATURE WITH PATHOLOGIC RESPONSE AND OUTCOME AFTER NEOADJUVANT PEMBROLIZUMAB (PEMBRO), COMPARED TO NEOADJUVANT CHEMOTHERAPY (NAC), IN MUSCLE-INVASIVE BLADDER CANCER (MIBC) The Journal of Urology. 203: e841 |
| Rouprêt M, Malmstrom PU, Black P. (2019) Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options? European Urology Oncology |
| Lotan* Y, Boorjian S, Zhang J, et al. (2019) MP26-15 MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING AT RADICAL CYSTECTOMY Journal of Urology. 201 |
| Costa JBD, Gibb EA, Bivalacqua TJ, et al. (2019) Molecular characterization of neuroendocrine-like bladder cancer European Urology Supplements. 18 |
| Lotan Y, Woldu SL, Sanli O, et al. (2018) Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Bju International |
| Woldu S, Sanli O, Black P, et al. (2018) Mp47-09 Cost-Effectiveness Analysis Of A Biomarker-Based Approach To Select Patients With Muscle-Invasive Bladder Cancer For Neoadjuvant Chemotherapy The Journal of Urology. 199 |
| Duplisea J, Metcalfe M, Sundi D, et al. (2018) MP47-04 REFINING SELECTION CRITERIA FOR NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: COMBINING CLINICAL RISK FEATURES AND INTRINSIC MOLECULAR SUBTYPES Journal of Urology. 199 |
| Frees SK, Aning J, Black P, et al. (2017) A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. World Journal of Urology |